Compare PLSE & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | INSP |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2015 | 2018 |
| Metric | PLSE | INSP |
|---|---|---|
| Price | $44.92 | $58.20 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 16 |
| Target Price | $22.00 | ★ $94.00 |
| AVG Volume (30 Days) | 405.5K | ★ 794.5K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | $840.00 | $8.02 |
| Revenue Next Year | $287.54 | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $12.56 | $38.91 |
| 52 Week High | $45.90 | $147.03 |
| Indicator | PLSE | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 77.11 | 60.52 |
| Support Level | $24.27 | $57.57 |
| Resistance Level | N/A | $59.40 |
| Average True Range (ATR) | 3.21 | 2.48 |
| MACD | 0.82 | 0.23 |
| Stochastic Oscillator | 88.51 | 56.52 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.